Haemonetics is a leading global healthcare company (NYSE: HAE) founded in 1971. It is dedicated to providing innovative medical products and solutions in the biotechnology and healthcare industries, aimed at improving patient care and reducing healthcare costs. The company's focus areas include blood and plasma component collection, the surgical suite, and hospital transfusion services. Haemonetics recently secured a $600.00M Post-IPO Debt investment on 21 May 2024. For more information about Haemonetics, visit www.haemonetics.com.
Funding Stage | Amount | No. Investors | Investors | Date |
---|---|---|---|---|
Post-IPO Debt | $600.00M | - | 21 May 2024 | |
Post-IPO Equity | $435.00M | - | 01 Mar 2021 | |
Post-IPO Equity | $10.00M | - | 23 May 2019 | |
Post-IPO Debt | $700.00M | - | 18 Jun 2018 |
No recent news or press coverage available for Haemonetics.